Boditech Med Valuation
Is A206640 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of A206640 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: A206640 (₩16260) is trading below our estimate of fair value (₩34301.18)
Significantly Below Fair Value: A206640 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for A206640?
Key metric: As A206640 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is A206640's PE Ratio? | |
|---|---|
| PE Ratio | 11.7x |
| Earnings | ₩30.44b |
| Market Cap | ₩357.32b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2.2x |
| Enterprise Value/EBITDA | 8x |
| PEG Ratio | 0.7x |
Price to Earnings Ratio vs Peers
How does A206640's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 8.2x | ||
A336570 WON TECHLtd | 13.9x | 38.4% | ₩393.5b |
A043150 Value Added Technology | 5.7x | 10.8% | ₩300.8b |
A041830 InBodyLtd | 7.9x | 15.5% | ₩289.2b |
A145720 Dentium | 5.3x | 13.8% | ₩501.0b |
A206640 Boditech Med | 11.7x | 16.6% | ₩357.3b |
Price-To-Earnings vs Peers: A206640 is expensive based on its Price-To-Earnings Ratio (11.7x) compared to the peer average (8.2x).
Price to Earnings Ratio vs Industry
How does A206640's PE Ratio compare vs other companies in the KR Medical Equipment Industry?
| 1 Company | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
A035610 Solborn | 2.5x | n/a | US$67.17m |
| 1 Company | Estimated Growth | Market Cap |
|---|
Price-To-Earnings vs Industry: A206640 is good value based on its Price-To-Earnings Ratio (11.7x) compared to the KR Medical Equipment industry average (12.9x).
Price to Earnings Ratio vs Fair Ratio
What is A206640's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 11.7x |
| Fair PE Ratio | 15.1x |
Price-To-Earnings vs Fair Ratio: A206640 is good value based on its Price-To-Earnings Ratio (11.7x) compared to the estimated Fair Price-To-Earnings Ratio (15.1x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | ₩16,260.00 | ₩24,500.00 +50.7% | 6.1% | ₩26,000.00 | ₩23,000.00 | n/a | 2 |
| Nov ’25 | ₩15,260.00 | ₩24,500.00 +60.6% | 6.1% | ₩26,000.00 | ₩23,000.00 | n/a | 2 |
| Oct ’25 | ₩16,700.00 | ₩24,500.00 +46.7% | 6.1% | ₩26,000.00 | ₩23,000.00 | n/a | 2 |
| Sep ’25 | ₩18,260.00 | ₩24,500.00 +34.2% | 6.1% | ₩26,000.00 | ₩23,000.00 | n/a | 2 |
| Aug ’25 | ₩17,700.00 | ₩24,500.00 +38.4% | 6.1% | ₩26,000.00 | ₩23,000.00 | n/a | 2 |
| Jul ’25 | ₩17,200.00 | ₩24,500.00 +42.4% | 6.1% | ₩26,000.00 | ₩23,000.00 | n/a | 2 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.
Discover undervalued companies
Access Bio
₩191.4b
Engages in the research, development, and manufacture of in vitro rapid diagnostic tests, biosensors, and molecular diagnostic products worldwide.
A950130
₩5,660.00
7D
-3.4%
1Y
-38.1%
Wonbiogen
₩44.6b
Develops and sells medical equipment in South Korea.
A307280
₩1,258.00
7D
-3.7%
1Y
-20.0%
Sewoon Medical
₩112.8b
Engages in the research and development, manufacture, and sale of medical products in South Korea.
A100700
₩2,605.00
7D
-0.6%
1Y
-5.3%